Secretory PLA2inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFα-stimulated human endothelial cells
Authors:
Open Access
- 1 April 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (7) , 1399-1408
Abstract
Background and purpose: Secretory phospholipase A2 (sPLA2) is implicated in atherosclerosis, although the effects of specific sPLA2 inhibitors have not been studied. We investigated the effects of the indole analogue indoxam on low‐density lipoprotein (LDL) modification by sPLA2 enzymes of different types and on the associated inflammatory responses in human umbilical vein endothelial cells (HUVEC). Experimental approach: LDL modification was assessed by measuring the contents of two major molecular species of lysophosphatidylcholine (LPC) using electrospray ionization‐liquid chromatography/mass spectrometry. The proinflammatory activity of the modified LDL was evaluated by determining monocyte chemoattractant protein‐1 (MCP‐1) mRNA expression and transcriptional factor nuclear factor‐kappaB (NF‐κB) activity in HUVEC. Key results: Indoxam dose‐dependently inhibited palmitoyl‐ and stearoyl‐LPC production in LDL incubated with snake venom sPLA2 (IC50 1.2 μM for palmitoyl‐LPC, 0.8 μM for stearoyl‐LPC). MCP‐1 mRNA expression and NF‐κB activity were enhanced by venom sPLA2‐treated LDL, which was completely suppressed by indoxam but not by thioetheramide‐PC, a competitive sPLA2 inhibitor. Indoxam also suppressed LPC production in LDL treated with human synovial type IIA sPLA2. Tumour necrosis factor α (TNFα) increased type V sPLA2 expression in HUVEC. Indoxam dose‐dependently suppressed LPC production in native and glycoxidized LDL treated with TNFα‐stimulated HUVEC. Indoxam suppressed MCP‐1 mRNA expression and NF‐κB activity in TNFα‐stimulated HUVEC incubated with native or glycoxidized LDL. Conclusions and implications: Indoxam prevented sPLA2‐induced LPC production in native and glycoxidized LDL as well as LDL‐induced inflammatory activity in HUVEC. Our results suggest that indoxam may be a potentially useful anti‐atherogenic agent. British Journal of Pharmacology (2008) 153, 1399–1408; doi:10.1038/bjp.2008.12; published online 11 February 2008Keywords
This publication has 47 references indexed in Scilit:
- Secretory Phospholipase A2Group VArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2005
- Autocrine and Paracrine Transcriptional Regulation of Type IIA Secretory Phospholipase A2 Gene in Vascular Smooth Muscle CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and WomenArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Phospholipase A2 enzymesProstaglandins & Other Lipid Mediators, 2002
- Secretory Phospholipase A2 Mediates Cooperative Prostaglandin Generation by Growth Factor and Cytokine Independently of Preceding Cytosolic Phospholipase A2 Expression in Rat Gastric Epithelial CellsJournal of Biological Chemistry, 2001
- Role of Group II Secretory Phospholipase A2in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Localization of Nonpancreatic Secretory Phospholipase A 2 in Normal and Atherosclerotic ArteriesArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Potent Inhibitors of Secretory Phospholipase A2: Synthesis and Inhibitory Activities of Indolizine and Indene DerivativesJournal of Medicinal Chemistry, 1996
- Correlation of Enzymatic Activity and Anticoagulant Properties of Phospholipase A2European Journal of Biochemistry, 1980